AYTU BIOPHARMA, INC — Director's Dealing 2021

Mar 31, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AYTU BIOPHARMA, INC (AYTU)
CIK: 0001385818
Period of Report: 2021-03-19

Reporting Person: McLaughlin Gerald W. (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	24901	Direct

Footnotes

F1: Includes restricted stock units and common stock of Neos Therapeutics, Inc., previously held by the reporting person, which converted into common stock of the Issuer at an exchange rate of 0.1088 pursuant to the terms of a merger agreement dated December 10, 2020, filed with the Securities and Exchange Commission as Exhibit 2.1 to the Issuer's 8-K dated March 22, 2021.